Tradestie Institutional Equity Comparison Engine

AGEN vs CVM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AGEN Overall Edge

AGEN Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Agenus Inc. (AGEN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, AGEN trades at 3.7x Forward P/E with 38.9% operating margin (+4.1% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, AGEN sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
AGEN 3.7x vs CVM 23.0x Fwd P/E
Growth & Margin Winner AGEN
Op Margin 38.9% vs 0.0% ยท YoY +4.1% vs -62.7%
Momentum & Technical Winner AGEN
1Y +46.4% vs -77.5% ยท 52W Pos 48% vs 10%
Options & Structure Winner AGEN
BREAKDOWN (11th %ile IV) vs BREAKDOWN (N/A IV)
AGEN NASDAQ
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.34
-5.79% 1D
Market Cap $310.8M
1M Return +4.97%
1Y Return +46.42%
Forward P/E 3.7x
Unified AI Score
51.5 / 100 HOLD
Tech 49.0 Fund 55.0 Flow 66.0 Mom 50.0
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
1M Return -11.17%
1Y Return -77.48%
Forward P/E 23.0x
Unified AI Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AGEN +46.42% CVM -77.48% Spread: +122.06 pp (AGEN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period AGEN Revenue CVM Revenue AGEN Op. Margin CVM Op. Margin Margin Edge
FY2018 $40M N/A -336.6% N/A AGEN
FY2019 $150M N/A -46.7% N/A AGEN
FY2020 $90M N/A -133.0% N/A AGEN
FY2021 $300M N/A 8.7% N/A AGEN
FY2022 $100M N/A -183.0% N/A AGEN
FY2023 $160M N/A -102.1% N/A AGEN
FY2024 $100M N/A -116.4% N/A AGEN
FY2025 $110M N/A -17.7% N/A AGEN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AGEN (7) vs CVM (3)
Institutional Metric AGEN CVM Criterion Row Winner
Market Capitalization Scale $310.8M $20.9M Larger Scale AGEN
Trailing P/E Ratio Valuation 29.9x 23.0x Lower Multiple CVM
Forward P/E Ratio Valuation 3.7x 23.0x Lower Multiple AGEN
Revenue Growth (YoY) Growth +4.1% -62.7% Higher Growth AGEN
Operating Margin (TTM) Profitability 38.9% 0.0% Higher Margin AGEN
Net Profit Margin Profitability 30.8% 0.0% Higher Margin AGEN
Return on Equity (ROE) Capital Efficiency -1278.8% -252.5% Higher ROE CVM
52-Week Range Position Momentum 48% ($3โ€“$10) 10% ($1โ€“$8) Stronger Trend AGEN
Beta / 30D Volatility Risk Regime 1.60ฮฒ ยท 76% Vol 0.65ฮฒ ยท 120% Vol Lower Realized Risk AGEN
Unified Institutional Score Composite Signal 51.5 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AGEN vs CVM Buy Guide
AGEN BREAKDOWN
33d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live AGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AGEN nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.